

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/916,440	07/30/2001	Jing Wu	002010-586	2003	
21839	7590 06/12/2003				
	ANE SWECKER & N	EXAMINER			
POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404			KIFLE, BRUCK		
			ART UNIT	PAPER NUMBER	
		·	1624	10	
	•		DATE MAILED: 06/12/2003	19	

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. **09/916,440**

Applicant(s)

Wu et al.

Examiner

Bruck Kifle, Ph.D.

t Unit 1624



		on the cover she	et with t	The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
	for Reply	TO EVAIDE	2	-NAONTHIC FROM					
	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE3MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.								
- Extens	- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the								
- If the p	mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.								
	- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).								
	ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	his communication, eve	en if timely 1	filed, may reduce any					
Status	,								
1) 💢	Responsive to communication(s) filed on Mar 31, 2	2003		·					
2a) 🗌	This action is FINAL . 2b) 💢 This action	ion is non-final.							
3) 🗆	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.								
Disposit	tion of Claims								
4) 💢	Claim(s) 91, 96-103, 105-108, 118, 125-130, and	132-135		is/are pending in the application.					
4	la) Of the above, claim(s)			is/are withdrawn from consideration.					
5) 🗆	Claim(s) .			is/are allowed.					
6) 💢	Claim(s) 91, 96-103, 105-108, 118, 125-130, and	132-135		is/are rejected.					
7) 🗌	Claim(s)			is/are objected to.					
8) 🗌	Claims	are	subject 1	to restriction and/or election requirement.					
Application Papers									
9) 🗌	The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are a) accepted or b) objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11)□	1) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
	If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.									
Priority under 35 U.S.C. §§ 119 and 120									
13) 🗌	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) [☐ All b)☐ Some* c)☐ None of:			•					
•	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).									
_	ee the attached detailed Office action for a list of the	•							
14)	Acknowledgement is made of a claim for domestic	•							
a) ∟		- *							
	Acknowledgement is made of a claim for domestic	priority under 3	5 U.S.C	§§ 120 and/or 121.					
Attachme	ent(s) stice of References Cited (PTO-892)	4) Tietaniau Sum	man, /PTO	413) Paper No(s)					
	stice of Draftsperson's Patent Drawing Review (PTO-948)	_		Application (PTO-152)					
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)			mai ratem.	Application (F10-132)					
-,		0, 0							

Prosecution in this case has been reopened after an appeals conference in the work group.

The examiner has been given a "reasonable" amount of time to expand the search to perform a "reasonable search". Thus, the finality of the rejection of the last Office action is withdrawn.

Applicant's amendments and remarks filed 3/31/03 have been entered. Claims 91, 96-103, 105-108, 118, 125-130 and 132-135 are now pending in this application.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Application/Control Number: 09/916,440 Page 3

Art Unit: 1624

Claims 91, 96-103, 105-108, 118, 125-130 and 132-135 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-34 of U.S. Patent No. 6,552,013. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instantly claimed compounds differ by varying the length of the linker Z' over the patented claims.

It has been long established that structural relationship varying the size of a linking carbon chain - is per se obvious. Specifically, In re Shetty, 195 USPQ 753, In re Wilder, 195 USPQ 426 and Ex Parte Greshem 121 USPQ 422 all feature a compound with a C_2 link rejected over a compound with a C_1 link. Similarly, In re Chupp, 2 USPQ 2nd 1437 and In re Coes, 81 USPQ 369 have a C_1 link unpatentable over a C_2 link. Ex parte Ruddy 121 USPQ 427 has a C_3 link unpatentable over a C_1 link. Ex parte Nathan, 121 USPQ 349 found the insertion of a C_2H_4 link obvious. In all of these cases, the variation was per-se obvious and did not require a specific teaching.

Applicants' attention is directed to US 6,432,944, which while not competent reference against instant claims, claims identical subject matter to that claimed herein. The only way to overcome such an application is by way of Interference proceedings or removal of the conflicting subject matter. See MPEP 2306.

Application/Control Number: 09/916,440 Page 4

Art Unit: 1624

Claim Rejections - 35 USC § 112

Claims 91, 96-103, 105-108, 118, 125-130 and 132-135 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification is not adequately enabling for the scope of the compounds claimed.

All of the compounds made are drawn to a narrow group which does NOT give a reasonable assurance that all, or substantially all of them, are useful. The claims are not drawn in terms of a recognized genus but are directed to a more or less artificial selection of compounds.

There is no reason why a claim drawn in this way should not be limited to those compounds which are shown to be both new and useful. An Applicant is not entitled to a claim for a large group of compounds merely on the basis of a showing that a selected few are useful and a general suggestion of a similar utility in the others.

Also, see In re Surrey 151 USPQ 724, regarding sufficiency of a disclosure for a Markush group, and MPEP 2164.03 for enablement requirements in cases directed to structure-sensitive arts such as the instant pharmaceutical arts. Note in Surrey, in which testing done on a group of homogeneous compounds having the same core was deemed NOT sufficient to support claims to various hetero groups of a much narrower range than is being claimed herein and located at only one position in the formula. The instant scope is enormous, in the billions of compounds, and

therefore one compound within its scope is not remotely representative of such a scope. See MPEP 2164.03.

Provisos

There are provisos in the claims that exclude compounds embraced by the claims. If these provisos are present to avoid prior art, applicants are urgently requested to point out these references to the examiner because of their importance in the examination of the claims. Applicants have not respond to this query. For example, should the compound excluded by proviso in AAA be present in the prior art, this compound would render claim 118 obvious because the claim embraces a compound wherein (all else being the same) R¹ is 2,5difluorophenyl (or 4,5-difluorophenyl) or a compound wherein (again all else being the same) R² is ethyl. These compounds are embraced by the instant claim and represent a ring position isomer and a homologue, respectively, of the excluded compound. Should the compound AAA be present in the prior art, claim 118 would be rejected under 35 USC 103 because compounds that differ only by the presence of an extra methyl group are homologues which are of such close structural similarity that the disclosure of a compound renders prima facie obvious its homologue. The homologue is expected to be prepareable by the same method and to have the same properties. This expectation is then deemed the motivation for preparing homologues. Homologues are obvious even in the absence of a specific teaching to methylate, In re Wood 199 USPQ 137; In re Hoke 195 USPQ 148; In re Lohr 137 USPQ 548; In re Magerlein 202 USPQ 473; In re Wiechert 152 USPQ 249; Ex parte Henkel 130 USPQ 474; In re Fauque 121 USPQ

425; In re Druey 138 USPQ 39. In all of these cases, the close structural similarity of two compounds differing by only one (or two) methyl groups sufficed; no specific teaching to methylate was present or required. None of these cases has been overruled and indeed the examiner is unaware of any post Lohr case in which motivation is required to put a methyl group on an old compound.

Alternatively, position isomers are well established as being prima facie structurally obvious. See: Ex parte Engelhardt, 208 USPQ 343, 349; In re Mehta, 146 USPQ 284; In re Surrey, 138 USPO 67; Ex parte Ullyot 103 USPO 185; Ex parte Naito 168 USPO 437, 439; In re Norris 84 USPQ 459; Ex parte Allais 152 USPQ 66; Ex parte Henkel 130 USPQ 474; Ex parte Biel 124 USPQ 109; In re Crownse 150 USPQ 554; In re Fouche 169 USPQ 431; Ex parte Ruddy 121 USPQ 427; In re Wiechert 152 USPQ 249.

For example "Position Isomerism has been used as a tool to obtain new and useful drugs" (Engelhardt), and Position isomerism is a fact of close structural similarity" (Mehta, emphasis in the original).

The search revealed that the elected compound is disclosed in several of Applicants pending applications. See for example WO 99/67221 and WO 98/28268. Also, WO 2001/034571 overlaps generically. Applicants are required to maintain a clear line of demarcation between the corresponding US applications and the instant application. See MPEP § 822. Applicants need to point out what the differences in scopes are.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle whose telephone number is (703) 305-4484.

The fax phone number for this Group is (703) 308-4556 or (703) 305-3592. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

June 11, 2003

Bruck Kifle'
Primary Examiner
Art Unit 1624